Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.

MLA

Acharya, Nisha R., et al. “Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.” American Journal of Ophthalmology, vol. 267, Nov. 2024, pp. 100–11. EBSCOhost, https://doi.org/10.1016/j.ajo.2024.06.004.

APA

Acharya, N. R., Rathinam, S. R., Thundikandy, R., Kanakath, A., Murugan, S. B., Vedhanayaki, R., Gonzales, J. A., Lim, L. L., Suhler, E. B., Al-Dhibi, H. A., Doan, T., Arellanes-Garcia, L., Coyne, A., Porco, T. C., & Shantha, J. G. (2024). Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial. American Journal of Ophthalmology, 267, 100–111. https://doi.org/10.1016/j.ajo.2024.06.004

Chicago

Acharya, Nisha R, Sivakumar R Rathinam, Radhika Thundikandy, Anuradha Kanakath, S Bala Murugan, R Vedhanayaki, John A Gonzales, et al. 2024. “Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.” American Journal of Ophthalmology 267 (November): 100–111. doi:10.1016/j.ajo.2024.06.004.